KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to -$2.5 billion.

  • Pfizer's Cash from Financing Activities rose 7940.3% to -$2.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$22.9 billion, marking a year-over-year decrease of 6406.18%. This contributed to the annual value of -$17.1 billion for FY2024, which is 16575.62% down from last year.
  • Pfizer's Cash from Financing Activities amounted to -$2.5 billion in Q3 2025, which was up 7940.3% from -$3.2 billion recorded in Q2 2025.
  • Pfizer's 5-year Cash from Financing Activities high stood at $27.2 billion for Q3 2023, and its period low was -$12.0 billion during Q3 2024.
  • In the last 5 years, Pfizer's Cash from Financing Activities had a median value of -$3.0 billion in 2021 and averaged -$1.9 billion.
  • In the last 5 years, Pfizer's Cash from Financing Activities soared by 97833.33% in 2023 and then plummeted by 21823.23% in 2024.
  • Pfizer's Cash from Financing Activities (Quarter) stood at -$6.5 billion in 2021, then crashed by 51.88% to -$9.8 billion in 2022, then skyrocketed by 155.42% to $5.4 billion in 2023, then crashed by 320.98% to -$12.0 billion in 2024, then skyrocketed by 79.4% to -$2.5 billion in 2025.
  • Its Cash from Financing Activities was -$2.5 billion in Q3 2025, compared to -$3.2 billion in Q2 2025 and -$5.2 billion in Q1 2025.